首页
登录
职称英语
Cigarettes Are Enlisted to Test Ways of Quitting When a truc
Cigarettes Are Enlisted to Test Ways of Quitting When a truc
游客
2023-07-09
49
管理
问题
Cigarettes Are Enlisted to Test Ways of Quitting
When a truck recently delivered 45 000 cartons of cigarettes to a research company in North Carolina, it was a turning point in the government’s war on smoking.
These were no ordinary cigarettes, but experimental ones, made of genetically altered tobacco to lower the nicotine content by 97 percent while preserving all the other tastes and smells and rituals for smokers of conventional cigarettes.
Researchers had been seeking a new and bigger supply because shortages had limited previous studies to just dozens of people. The experimental cigarettes are produced by a Massachusetts company, the 22nd Century Group, which holds 98 patents for genetic manipulation of tobacco plants to reduce or increase the amount of nicotine in cigarettes.
The National Institutes of Health(NIH)bought nine million of these cigarettes, marked "for research purposes only," from the 22nd Century Group as part of a broadening scientific effort to find ways to regulate cigarettes so that they are nonaddictive. The Spectrum brand test cigarettes have eight different levels of nicotine for research, from a nicotine content of 3 percent to 100 percent of the nicotine in the best-selling Marlboro Gold, though a 97 percent reduction is the most common level.
Dr. Nora D. Volkow, director of the National Institute on Drug Abuse of the NIH, which oversees the work, called the delivery crucial for the new federal research projects. These include last month’s award of $2.5 million for the first year of a planned five-year series of studies into threshold(门槛)levels of nicotine addiction and the possible impact of a sharp reduction in nicotine on smoking and public health.
One study of the test cigarettes will follow about 500 smokers over six months to determine whether they are more likely to quit if they switch to those cigarettes quickly or gradually. The research, led by Dorothy K. Hatsukami, a professor of psychiatry at the University of Minnesota, and Eric C. Donny, associate professor of psychology at the University of Pittsburgh, will use about 1.5 million of the recently acquired cigarettes.
For researchers, the availability of a new supply of test cigarettes is "a game changer," said Mitch Zeller, co-chairman of the Tobacco Harm Reduction Network at the National Cancer Institute and a consultant on nicotine replacement products. "It’s still all about the nicotine. Only now we have the power to do something about it. "
At the same time, officials in the $80 billion tobacco industry have warned of unexpected side effects from addiction withdrawal and black market products, complex issues the Food and Drug Administration(FDA)will have to study in considering regulation.
Under a 2009 law giving the FDA authority over tobacco products, the agency cannot ban nicotine, but can require that it be reduced to extremely low levels if that is proved to benefit public health.
"We really need to have good science to determine whether this might be a product standard, and to have good science, we need reduced-nicotine cigarettes," said Dr. Hatsukami, who is also a member of the FDA Tobacco Products Scientific Advisory Committee. Her work stalled when companies stopped making very-low-nicotine cigarettes. "In the middle of a study, we don’t have the cigarettes," she said.
"No one has ever sought FDA approval of a cigarette as a medical device," Joseph Pandolfino, the founder and chief executive of 22nd Century, said in an interview. Preliminary studies show smokers can have an easier time quitting if they cut down on the nicotine while still being able to do all the other things they do with cigarettes, he said, but larger studies are needed.
The growing industry of quit-smoking products has not further dented(削减)the rather steady rate of smoking recently in the United States, which has stayed at about 20 percent since 2004 after years of notable decline. A new crop of electronic cigarettes and smokeless tobacco products seem aimed more at getting smokers through smoke-free times rather than quitting.
Earlier this month, the FDA and NIH also announced they were starting a $ 118 million study to track about 44 000 people over five years to assess usage trends, risk perception, quit-smoking attempts and the possible impact of new tobacco regulations. In 2006, a federal judge found that tobacco companies had designed cigarettes to precisely control the amount of nicotine and provide doses sufficient for addiction, while concealing much of their nicotine research. They marketed so-called light cigarettes, which delivered a lower dose to smoking machines because of holes in the filter, but the same dose or worse to smokers who compensated by covering the holes with their lips and drawing harder.
In two small studies by Dr. Hatsukami and Dr. Benowitz, the genetically altered cigarettes were found to defeat the phenomenon of smoker "compensation." But researchers said they needed much more evidence.
Tests so far on the experimental cigarettes are encouraging enough that Dr. Hatsukami is going into a Phase 3 clinical trial. That means Phase 2 trials have proven effectiveness on humans. Phase 3 measures both effectiveness and safety. 22nd Century is also planning to start Phase 3 trials next year.
The studies are examining gradual or rapid reductions of nicotine. In a regulated marketplace, the government could set limits on nicotine and ratchet down(逐步减少). And teenagers could still experiment with cigarettes, as they are wont to do, without getting addicted.
"It’s a hot topic," said Clifford E. Douglas, director of the University of Michigan Tobacco Research Network. "But as difficult as menthol(薄荷醇)has been, nicotine will be more difficult, because it’s not 15 million smokers, it’s every smoker in the United States." The FDA’s advisory panel has not put nicotine pn its agenda yet, which is why Dr. Gregory N. Connolly, a Harvard professor of public health and antismoking advocate, said he resigned from the FDA panel in December.
"After 50 years of knowing cigarettes cause cancer, it’s nice to know we have a supply we can investigate," Dr. Connolly said. "But the real issue is the FDA should have begun a process two years ago to see if we can eliminate nicotine in cigarettes, at least for children. If we can put a man on the moon, we can get rid of nicotine. " [br] The 2009 law entitles the FDA to______.
选项
A、put an end to the nicotine present in cigarettes
B、get rid of negative effects of nicotine addiction
C、develop new products beneficial to public health
D、require the reduction of the nicotine content
答案
D
解析
转载请注明原文地址:https://www.tihaiku.com/zcyy/2822563.html
相关试题推荐
Thebenefitsofquittingsmoking—reducedriskofcancerandmanyotherhealt
Thebenefitsofquittingsmoking—reducedriskofcancerandmanyotherhealt
Thebenefitsofquittingsmoking—reducedriskofcancerandmanyotherhealt
Thebenefitsofquittingsmoking—reducedriskofcancerandmanyotherhealt
Thebenefitsofquittingsmoking—reducedriskofcancerandmanyotherhealt
CigarettesAreEnlistedtoTestWaysofQuittingWhenatruc
CigarettesAreEnlistedtoTestWaysofQuittingWhenatruc
CigarettesAreEnlistedtoTestWaysofQuittingWhenatruc
CigarettesAreEnlistedtoTestWaysofQuittingWhenatruc
CigarettesAreEnlistedtoTestWaysofQuittingWhenatruc
随机试题
WhatdoestheManMean?[br][originaltext]W:ThestoryWasveryinteresting.M:I
[originaltext](16)Attractingandfeedingwildbirdsareentertainingactivitie
患者,男性,29岁,颜面和双下肢水肿伴少尿5个月,查血压140/95mmHg,尿
男性,28岁。2周前因咳嗽、咯血伴发热,痰抗酸杆菌(+++),下列治疗方案首选哪
八正散与茵陈蒿汤二方中均含有A.柴胡与大黄 B.大黄与山栀 C.黄芩与黄
伤寒发病第一周用于细菌分离培养标本为A.血液B.尿液C.粪便D.骨髓E.痰
各种运输方式内外部的各个方面的构成和联系,就是( )。 A.运输系统
关于承接查验,下列说法不正确的是()。A.新建物业承接查验是以主体结构安
依据《建筑设计防火规范》(GB50016-2014),对某高层公共建筑进行的下
某12层住宅楼采用筏板基础,基础下土层为:①粉质黏土,厚约2.0m;②淤泥质土,
最新回复
(
0
)